ResearchSpace

Combined atomistic molecular calculations and experimental investigations for the architecture, screening, optimization, and characterization of pyrazinamide containing oral film formulations for tuberculosis management

Show simple item record

dc.contributor.author Adeleke, Oluwatoyin A
dc.contributor.author Monama, Nkwe O
dc.contributor.author Tsai, PC
dc.contributor.author Sithole, Happy M
dc.contributor.author Michniak-Kohn, BB
dc.date.accessioned 2021-12-06T09:22:50Z
dc.date.available 2021-12-06T09:22:50Z
dc.date.issued 2015-12
dc.identifier.citation Adeleke, O.A., Monama, N.O., Tsai, P., Sithole, H.M. & Michniak-Kohn, B. 2015. Combined atomistic molecular calculations and experimental investigations for the architecture, screening, optimization, and characterization of pyrazinamide containing oral film formulations for tuberculosis management. <i>Molecular Pharmaceutics, 13(2).</i> http://hdl.handle.net/10204/12196 en_ZA
dc.identifier.issn 1543-8384
dc.identifier.uri DOI: 10.1021/acs.molpharmaceut.5b00698
dc.identifier.uri http://hdl.handle.net/10204/12196
dc.description.abstract To date, effective treatment, prophylaxis, and control of tuberculosis (TB) infection is mainly dependent on the use of drugs. However, patient noncompliance with prescribed anti-TB treatment schemes remains a major problem confronting successful pharmacotherapeutic outcomes. Thus, the development of alternative delivery systems that can improve adherence for the existing anti-TB bioactives has been intensified in recent times. The aim of this investigation was to engineer an optimal, thermodynamically stable oral film (OF) formulation containing a key anti-TB agent, pyrazinamide (PYZ), employing molecular modeling and experimental tools. Four PYZ-loaded film variants (OF 1, OF 2, OF 3, OF 4) were constructed in silico and then prepared in vitro using the Accelrys Materials Studio software and solvent casting method, respectively. Screening and selection of the optimal OF was based on the computation of the total interaction energy (ET), kinetic energy (EK), solubility parameter (S), and cohesive energy density (CED) as well as determining mass, thickness, dissolution and disintegration times, dissolution pH, drug loading capacity, and surface morphology in vitro. OF 2 was selected as the optimal formulation as it displayed the lowest ET (−8006.28 kcal/mol), dissolution time (9.96 min), disintegration time (56.49 s), and weight (39.33 mg); moderate EK (1052.98 kcal/mol); highest S (44.55 (J/cm3)0.5) and CED (1.99 × 109 J/m3), slim dimension (166 μm), good and unvarying drug loading capacity (98.04%), acceptable dissolution pH (6.70), and well-layered surface topography. The drug release behavior of the optimal OF 2 was best elucidated with the zero order (R2 = 0.97) and Korsmeyer–Peppas (R2 = 0.99) models. X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), and differential scanning calorimetry (DSC) analyses showed that OF 2 was made of physically mixed multiple component polymeric and nonpolymeric compounds. OF 2 was semicrystalline in nature and displayed a dual phased ex vivo mucosal permeation pattern. In silico and in vitro physicomechanical quantities revealed OF 2’s flexibility, robustness, and compressibility. OF 2 was most stable under controlled environmental humidity, pressure, and temperature conditions in silico and in vitro. OF 2 was potentially non-cytotoxic and biocompatible. Succinctly, this work demonstrated the applicability of a combination of atomistic molecular mechanics and dynamics calculations as well as experimental analyses to the fabrication, screening, optimization, and characterization of drug formulations. Lastly, the fabricated OF 2 formulation can function as a potential alternative for the effective loading and delivery of PYZ. en_US
dc.format Abstract en_US
dc.language.iso en en_US
dc.relation.uri https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.5b00698 en_US
dc.relation.uri https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.5b00698 en_US
dc.relation.uri http://www.ncbi.nlm.nih.gov/pubmed/26650101 en_US
dc.source Molecular Pharmaceutics, 13(2) en_US
dc.subject Atomistic calculations en_US
dc.subject Computer-aided drug formulation en_US
dc.subject Experimental analyses en_US
dc.subject Molecular dynamics en_US
dc.subject Molecular mechanics en_US
dc.subject Orally disintegrating films en_US
dc.subject Physicochemical and physicomechanical characterization en_US
dc.subject Pyrazinamide en_US
dc.subject Thermodynamically stable en_US
dc.subject Tuberculosis en_US
dc.title Combined atomistic molecular calculations and experimental investigations for the architecture, screening, optimization, and characterization of pyrazinamide containing oral film formulations for tuberculosis management en_US
dc.type Article en_US
dc.description.pages 456-471 en_US
dc.description.note © 2015 American Chemical Society. Due to copyright restrictions, the attached PDF file only contains the abstract of the full text item. For access to the full text item, please consult the publisher's website: https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.5b00698 en_US
dc.description.cluster Meraka Institute en_US
dc.description.impactarea CHPC en_US
dc.identifier.apacitation Adeleke, O. A., Monama, N. O., Tsai, P., Sithole, H. M., & Michniak-Kohn, B. (2015). Combined atomistic molecular calculations and experimental investigations for the architecture, screening, optimization, and characterization of pyrazinamide containing oral film formulations for tuberculosis management. <i>Molecular Pharmaceutics, 13(2)</i>, http://hdl.handle.net/10204/12196 en_ZA
dc.identifier.chicagocitation Adeleke, Oluwatoyin A, Nkwe O Monama, PC Tsai, Happy M Sithole, and BB Michniak-Kohn "Combined atomistic molecular calculations and experimental investigations for the architecture, screening, optimization, and characterization of pyrazinamide containing oral film formulations for tuberculosis management." <i>Molecular Pharmaceutics, 13(2)</i> (2015) http://hdl.handle.net/10204/12196 en_ZA
dc.identifier.vancouvercitation Adeleke OA, Monama NO, Tsai P, Sithole HM, Michniak-Kohn B. Combined atomistic molecular calculations and experimental investigations for the architecture, screening, optimization, and characterization of pyrazinamide containing oral film formulations for tuberculosis management. Molecular Pharmaceutics, 13(2). 2015; http://hdl.handle.net/10204/12196. en_ZA
dc.identifier.ris TY - Article AU - Adeleke, Oluwatoyin A AU - Monama, Nkwe O AU - Tsai, PC AU - Sithole, Happy M AU - Michniak-Kohn, BB AB - To date, effective treatment, prophylaxis, and control of tuberculosis (TB) infection is mainly dependent on the use of drugs. However, patient noncompliance with prescribed anti-TB treatment schemes remains a major problem confronting successful pharmacotherapeutic outcomes. Thus, the development of alternative delivery systems that can improve adherence for the existing anti-TB bioactives has been intensified in recent times. The aim of this investigation was to engineer an optimal, thermodynamically stable oral film (OF) formulation containing a key anti-TB agent, pyrazinamide (PYZ), employing molecular modeling and experimental tools. Four PYZ-loaded film variants (OF 1, OF 2, OF 3, OF 4) were constructed in silico and then prepared in vitro using the Accelrys Materials Studio software and solvent casting method, respectively. Screening and selection of the optimal OF was based on the computation of the total interaction energy (ET), kinetic energy (EK), solubility parameter (S), and cohesive energy density (CED) as well as determining mass, thickness, dissolution and disintegration times, dissolution pH, drug loading capacity, and surface morphology in vitro. OF 2 was selected as the optimal formulation as it displayed the lowest ET (−8006.28 kcal/mol), dissolution time (9.96 min), disintegration time (56.49 s), and weight (39.33 mg); moderate EK (1052.98 kcal/mol); highest S (44.55 (J/cm3)0.5) and CED (1.99 × 109 J/m3), slim dimension (166 μm), good and unvarying drug loading capacity (98.04%), acceptable dissolution pH (6.70), and well-layered surface topography. The drug release behavior of the optimal OF 2 was best elucidated with the zero order (R2 = 0.97) and Korsmeyer–Peppas (R2 = 0.99) models. X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), and differential scanning calorimetry (DSC) analyses showed that OF 2 was made of physically mixed multiple component polymeric and nonpolymeric compounds. OF 2 was semicrystalline in nature and displayed a dual phased ex vivo mucosal permeation pattern. In silico and in vitro physicomechanical quantities revealed OF 2’s flexibility, robustness, and compressibility. OF 2 was most stable under controlled environmental humidity, pressure, and temperature conditions in silico and in vitro. OF 2 was potentially non-cytotoxic and biocompatible. Succinctly, this work demonstrated the applicability of a combination of atomistic molecular mechanics and dynamics calculations as well as experimental analyses to the fabrication, screening, optimization, and characterization of drug formulations. Lastly, the fabricated OF 2 formulation can function as a potential alternative for the effective loading and delivery of PYZ. DA - 2015-12 DB - ResearchSpace DP - CSIR J1 - Molecular Pharmaceutics, 13(2) KW - Atomistic calculations KW - Computer-aided drug formulation KW - Experimental analyses KW - Molecular dynamics KW - Molecular mechanics KW - Orally disintegrating films KW - Physicochemical and physicomechanical characterization KW - Pyrazinamide KW - Thermodynamically stable KW - Tuberculosis LK - https://researchspace.csir.co.za PY - 2015 SM - 1543-8384 T1 - Combined atomistic molecular calculations and experimental investigations for the architecture, screening, optimization, and characterization of pyrazinamide containing oral film formulations for tuberculosis management TI - Combined atomistic molecular calculations and experimental investigations for the architecture, screening, optimization, and characterization of pyrazinamide containing oral film formulations for tuberculosis management UR - http://hdl.handle.net/10204/12196 ER - en_ZA
dc.identifier.worklist 16567 en_US
dc.identifier.worklist 25110 en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record